- Report
- February 2024
- 70 Pages
Australia
From €4446EUR$4,750USD£3,716GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1872EUR$2,000USD£1,565GBP
- Report
- September 2022
- 30 Pages
Global
From €2574EUR$2,750USD£2,151GBP
- Report
- August 2026
- 70 Pages
Australia
From €4446EUR$4,750USD£3,716GBP
- Report
- May 2026
- 200 Pages
Canada
From €2610EUR$2,789USD£2,182GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Report
- June 2025
- 200 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Report
- June 2025
- 250 Pages
United States
From €2610EUR$2,789USD£2,182GBP
- Report
- June 2025
- 300 Pages
Europe
From €3621EUR$3,869USD£3,027GBP
- Report
- June 2025
- 400 Pages
Global
From €4632EUR$4,949USD£3,872GBP
- Report
- May 2025
- 300 Pages
Global
From €4632EUR$4,949USD£3,872GBP
- Report
- August 2024
- 150 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Report
- June 2026
- 138 Pages
United Kingdom
From €3743EUR$3,999USD£3,129GBP
- Report
- March 2026
- 136 Pages
France
From €3743EUR$3,999USD£3,129GBP
- Report
- May 2024
- 140 Pages
Global
From €3743EUR$3,999USD£3,129GBP
- Report
- May 2024
- 128 Pages
Global
From €3743EUR$3,999USD£3,129GBP
- Report
- May 2024
- 140 Pages
Global
From €3743EUR$3,999USD£3,129GBP
- Report
- May 2024
- 139 Pages
Global
From €3743EUR$3,999USD£3,129GBP

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications.
The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more